Study (registration number) | Disease setting | Study phase | Experimental arm | Control arm | Total N | ≥65 years (%) | Elderly (N) | Young (N) | ||
Exp | Ctrl | Exp | Ctrl | |||||||
ARIEL3 (NCT01968213) | Platinum-sensitive | III | Rucaparib 1200 mg/daily | Placebo/daily | 564 | 37.2 | 138 | 72 | 237 | 117 |
VELIA/GOG-3005 (NCT02470585) | Primary advanced | III | Carboplatin AUC 6+paclitaxel 175 mg/mq q3w+veliparib 300 mg/daily or carboplatin AUC 6+paclitaxel 175 mg/mq+veliparib 300 mg → Veliparib 600–800 mg/daily maintenance | Carboplatin AUC 6+paclitaxel 175 mg/mq q3w+placebo/daily → Placebo/daily maintenance | 757 | 39.1 | 154 | 142 | 228 | 233 |
PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) | Primary advanced | III | Niraparib 200 or 300 mg/daily | Placebo/daily | 733 | 39.4 | 190 | 99 | 297 | 147 |
SOLO1 (NCT01844986) | Primary advanced | III | Olaparib 600 mg/daily | Placebo/daily | 391 | 13.8 | 35 | 19 | 225 | 112 |
PAOLA-1 (NCT02477644) | Primary advanced | III | Olaparib 600 mg/daily+bevacizumab 15 mg/kg q3w | Placebo/daily+bevacizumab 15 mg/kg q3w | 806 | 36.2 | 205 | 87 | 332 | 182 |
ENGOT-OV16/NOVA (NCT01847274) | Platinum-sensitive | III | Niraparib 300 mg/daily | Placebo/daily | 553 | 35.3 | 132 | 63 | 240 | 118 |
SOLO2/ENGOT-OV21 (NCT01874353) | Platinum-sensitive | III | Olaparib 300 mg/twice day | Placebo/twice day | 295 | 21.0 | 40 | 22 | 156 | 77 |
NORA (NCT03705156) | Platinum-sensitive | III | Niraparib 300 mg/daily | Placebo/daily | 265 | 14.0 | 25 | 12 | 152 | 76 |
AUC, area under the curve.